Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
6 hedge funds and large institutions have $119K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
11% less capital invested
Capital invested by funds: $134K → $119K (-$15K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$10.4K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$590 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
1
Ionic Capital Management
New York
| $53K | -$590 | -1,500 | -1% |
|
|
AIC
2
AWM Investment Company
New York
| $41K | – | – | – |
|
|
BA
3
BlackRock Advisors
Wilmington,
Delaware
| $14K | – | – | – |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| $6K | -$10.4K | -26,364 | -56% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4K | +$5.08K | +12,900 | New |
|
|
VIA
6
Vantage Investment Advisors
State College,
Pennsylvania
| $1K | – | – | – |
|
EYEGW Hedge Fund Activity: Q4 2016 in Review
6 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q4 2016, worth a combined $119K — down 11% from $134K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new EYEGW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $5.08K. The largest seller was Sabby Management, cutting an estimated $10.4K.
- 6 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q4 2016, up from 5 in Q3 2016.
- Funds reported $119K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q4 2016, down 11% quarter-over-quarter.
- 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q4 2016 was Susquehanna International Group, an estimated $5.08K added.
- The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q4 2016 was Sabby Management, an estimated $10.4K sold.
Based on aggregated 13F filings for Q4 2016.